Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $11.44 Consensus Target Price from Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $11.44.

MRVI has been the subject of a number of research analyst reports. Robert W. Baird raised their target price on Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. The Goldman Sachs Group lowered their price objective on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, July 9th. Finally, Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 target price on the stock.

Insider Transactions at Maravai LifeSciences

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the sale, the director now owns 20,150,005 shares of the company’s stock, valued at $197,671,549.05. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Institutional investors have recently made changes to their positions in the company. Blue Trust Inc. bought a new stake in Maravai LifeSciences in the second quarter worth about $44,000. GAMMA Investing LLC lifted its stake in shares of Maravai LifeSciences by 310.2% during the 2nd quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after acquiring an additional 2,711 shares during the last quarter. Bayesian Capital Management LP purchased a new position in Maravai LifeSciences during the 1st quarter valued at $643,000. Bamco Inc. NY grew its position in Maravai LifeSciences by 43.1% in the 1st quarter. Bamco Inc. NY now owns 2,123,651 shares of the company’s stock valued at $18,412,000 after acquiring an additional 640,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Maravai LifeSciences by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 73,595 shares of the company’s stock worth $639,000 after purchasing an additional 3,575 shares during the period. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 0.7 %

Shares of NASDAQ MRVI opened at $8.28 on Friday. The firm has a fifty day simple moving average of $8.47 and a two-hundred day simple moving average of $7.79. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $12.52. The company has a current ratio of 11.32, a quick ratio of 10.47 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $2.09 billion, a PE ratio of -8.36 and a beta of 0.02.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The company had revenue of $64.18 million during the quarter, compared to the consensus estimate of $60.84 million. Equities analysts expect that Maravai LifeSciences will post -0.15 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.